Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

Chrisann KyiEkaterina DoubrovinaQin ZhouSara KravetzAlexia IasonosCarol AghajanianPaul SabbatiniDavid SpriggsRichard J O'ReillyRoisin E O'Cearbhaill

Published in: Journal for immunotherapy of cancer (2022)

The authors describe the first human application of autologous WT1-sensitized T cells in the treatment of patients with recurrent ovarian, primary peritoneal, and fallopian tube carcinomas.

Keyphrases

endothelial cells
cell therapy
randomized controlled trial
stem cells
high grade
study protocol